Chase Sapphire Reserve Adds Free Peloton Strength+ Membership for Cardholders
Chase Sapphire Reserve Adds Free Peloton Strength+ Membership for Cardholders
Chase Sapphire Reserve Adds Free Peloton Strength+ Membership for Cardholders
Chase Sapphire Reserve cardholders now have a new way to use their benefits. The premium card, known for its travel perks, has added a $120 annual credit for Peloton memberships. This credit can be put toward the Peloton Strength+ app, even without owning any Peloton equipment. The Peloton membership credit must first be activated in the Chase account. Once enabled, it covers a full year of the Peloton Strength+ app at no extra cost. Unlike other Peloton services, this app focuses only on strength training, with no live classes or cardio options.
The app provides instructor-led workout programs and custom routines. Users can train with dumbbells, barbells, machines, or just their bodyweight, making it flexible for home or travel. Since no Peloton hardware is needed, the credit is open to all cardholders, not just bike owners. The Chase Sapphire Reserve already includes a $300 annual travel credit and other premium benefits. The Peloton credit adds another simple way to maximise the card’s value without extra spending.
For existing Chase Sapphire Reserve users, the Peloton credit offers a straightforward perk. It turns into a free year of structured strength training through the app. The flexibility of the program means cardholders can use it almost anywhere, with or without gym equipment.
How Walnuts Boost Heart, Brain and Gut Health This Nutrition Month
A daily handful of walnuts could transform your health. This Nutrition Month, unlock their power for energy, memory, and a stronger immune system.
New startup incentifi rewards employees for staying active with travel discounts
What if your morning jog could pay for your next vacation? This startup is turning fitness into real rewards—and employers are signing up.
New leptin reference values transform metabolic disorder diagnostics
A 12,500-person study finally solves a decades-old medical puzzle. Doctors now have precise tools to interpret leptin levels—changing how we diagnose hunger and obesity.
Greenwich LifeSciences reports 70-80% drop in breast cancer recurrence with GLSI-100
A breakthrough in breast cancer treatment emerges as early trial data hints at dramatic reductions in recurrence. But one side effect raises questions.